Selected research
Industry Research
Biologics Clinical Manufacturing CDMO Service Industry Research Report 2026
Market perspective
The global Biologics Clinical Manufacturing CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biologics Clinical Manufacturing CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biologics Clinical Manufacturing CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biologics Clinical Manufacturing CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biologics Clinical Manufacturing CDMO Service include Thermo Fisher Scientific, Lonza, Intertek, Charles River Laboratories, Bio-Rad, Element, ProPharma, Ascendia and Minaris Regenerative Medicine, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biologics Clinical Manufacturing CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biologics Clinical Manufacturing CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biologics Clinical Manufacturing CDMO Service Market by Company
Thermo Fisher Scientific
Lonza
Intertek
Charles River Laboratories
Bio-Rad
Element
ProPharma
Ascendia
Minaris Regenerative Medicine
TriLink BioTechnologies
Oakwood Labs
PiramalPharma Solutions
Boehringer-Ingelheim
Wuxi Apptec
Pharmaron Beijing
Asymchem Laboratories (Tianjin)
Porton
SEQENS
Biologics Clinical Manufacturing CDMO Service Segment by Type
Traditional API CDMO
Highly Potent API CDMO
Biologics Clinical Manufacturing CDMO Service Segment by Application
Big Pharmaceutical Companies
Small and Medium Pharmaceutical Companies
Biologics Clinical Manufacturing CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics Clinical Manufacturing CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics Clinical Manufacturing CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics Clinical Manufacturing CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biologics Clinical Manufacturing CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Traditional API CDMO
- Highly Potent API CDMO
Applications
- Big Pharmaceutical Companies
- Small and Medium Pharmaceutical Companies
Companies covered
- Thermo Fisher Scientific
- Lonza
- Intertek
- Charles River Laboratories
- Bio-Rad
- Element
- ProPharma
- Ascendia
- Minaris Regenerative Medicine
- TriLink BioTechnologies
- Oakwood Labs
- PiramalPharma Solutions
- Boehringer-Ingelheim
- Wuxi Apptec
- Pharmaron Beijing
- Asymchem Laboratories (Tianjin)
- Porton
- SEQENS
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biologics Clinical Manufacturing CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Traditional API CDMO
- 2.2.3 Highly Potent API CDMO
- 2.3 Biologics Clinical Manufacturing CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Big Pharmaceutical Companies
- 2.3.3 Small and Medium Pharmaceutical Companies
- 2.4 Assumptions and Limitations
3 Biologics Clinical Manufacturing CDMO Service Breakdown Data by Type
- 3.1 Global Biologics Clinical Manufacturing CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Biologics Clinical Manufacturing CDMO Service Forecasted Market Size by Type (2027-2032)
4 Biologics Clinical Manufacturing CDMO Service Breakdown Data by Application
- 4.1 Global Biologics Clinical Manufacturing CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Biologics Clinical Manufacturing CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biologics Clinical Manufacturing CDMO Service Market Perspective (2021-2032)
- 5.2 Global Biologics Clinical Manufacturing CDMO Service Growth Trends by Region
- 5.2.1 Global Biologics Clinical Manufacturing CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biologics Clinical Manufacturing CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Biologics Clinical Manufacturing CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Biologics Clinical Manufacturing CDMO Service Market Dynamics
- 5.3.1 Biologics Clinical Manufacturing CDMO Service Industry Trends
- 5.3.2 Biologics Clinical Manufacturing CDMO Service Market Drivers
- 5.3.3 Biologics Clinical Manufacturing CDMO Service Market Challenges
- 5.3.4 Biologics Clinical Manufacturing CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biologics Clinical Manufacturing CDMO Service Players by Revenue
- 6.1.1 Global Top Biologics Clinical Manufacturing CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global Biologics Clinical Manufacturing CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Biologics Clinical Manufacturing CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biologics Clinical Manufacturing CDMO Service Head Office and Area Served
- 6.4 Global Biologics Clinical Manufacturing CDMO Service Players, Product Type & Application
- 6.5 Global Biologics Clinical Manufacturing CDMO Service Manufacturers Established Date
- 6.6 Global Biologics Clinical Manufacturing CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
- 7.2 North America Biologics Clinical Manufacturing CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biologics Clinical Manufacturing CDMO Service Market Size by Country (2021-2026)
- 7.4 North America Biologics Clinical Manufacturing CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
- 8.2 Europe Biologics Clinical Manufacturing CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biologics Clinical Manufacturing CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe Biologics Clinical Manufacturing CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biologics Clinical Manufacturing CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
- 10.2 South America Biologics Clinical Manufacturing CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biologics Clinical Manufacturing CDMO Service Market Size by Country (2021-2026)
- 10.4 South America Biologics Clinical Manufacturing CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Lonza
- 12.2.1 Lonza Company Information
- 12.2.2 Lonza Business Overview
- 12.2.3 Lonza Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.2.4 Lonza Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.2.5 Lonza Recent Developments
- 12.3 Intertek
- 12.3.1 Intertek Company Information
- 12.3.2 Intertek Business Overview
- 12.3.3 Intertek Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.3.4 Intertek Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.3.5 Intertek Recent Developments
- 12.4 Charles River Laboratories
- 12.4.1 Charles River Laboratories Company Information
- 12.4.2 Charles River Laboratories Business Overview
- 12.4.3 Charles River Laboratories Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.4.4 Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.4.5 Charles River Laboratories Recent Developments
- 12.5 Bio-Rad
- 12.5.1 Bio-Rad Company Information
- 12.5.2 Bio-Rad Business Overview
- 12.5.3 Bio-Rad Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.5.4 Bio-Rad Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.5.5 Bio-Rad Recent Developments
- 12.6 Element
- 12.6.1 Element Company Information
- 12.6.2 Element Business Overview
- 12.6.3 Element Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.6.4 Element Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.6.5 Element Recent Developments
- 12.7 ProPharma
- 12.7.1 ProPharma Company Information
- 12.7.2 ProPharma Business Overview
- 12.7.3 ProPharma Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.7.4 ProPharma Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.7.5 ProPharma Recent Developments
- 12.8 Ascendia
- 12.8.1 Ascendia Company Information
- 12.8.2 Ascendia Business Overview
- 12.8.3 Ascendia Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.8.4 Ascendia Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.8.5 Ascendia Recent Developments
- 12.9 Minaris Regenerative Medicine
- 12.9.1 Minaris Regenerative Medicine Company Information
- 12.9.2 Minaris Regenerative Medicine Business Overview
- 12.9.3 Minaris Regenerative Medicine Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.9.4 Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.9.5 Minaris Regenerative Medicine Recent Developments
- 12.10 TriLink BioTechnologies
- 12.10.1 TriLink BioTechnologies Company Information
- 12.10.2 TriLink BioTechnologies Business Overview
- 12.10.3 TriLink BioTechnologies Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.10.4 TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.10.5 TriLink BioTechnologies Recent Developments
- 12.11 Oakwood Labs
- 12.11.1 Oakwood Labs Company Information
- 12.11.2 Oakwood Labs Business Overview
- 12.11.3 Oakwood Labs Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.11.4 Oakwood Labs Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.11.5 Oakwood Labs Recent Developments
- 12.12 PiramalPharma Solutions
- 12.12.1 PiramalPharma Solutions Company Information
- 12.12.2 PiramalPharma Solutions Business Overview
- 12.12.3 PiramalPharma Solutions Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.12.4 PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.12.5 PiramalPharma Solutions Recent Developments
- 12.13 Boehringer-Ingelheim
- 12.13.1 Boehringer-Ingelheim Company Information
- 12.13.2 Boehringer-Ingelheim Business Overview
- 12.13.3 Boehringer-Ingelheim Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.13.4 Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.13.5 Boehringer-Ingelheim Recent Developments
- 12.14 Wuxi Apptec
- 12.14.1 Wuxi Apptec Company Information
- 12.14.2 Wuxi Apptec Business Overview
- 12.14.3 Wuxi Apptec Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.14.4 Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.14.5 Wuxi Apptec Recent Developments
- 12.15 Pharmaron Beijing
- 12.15.1 Pharmaron Beijing Company Information
- 12.15.2 Pharmaron Beijing Business Overview
- 12.15.3 Pharmaron Beijing Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.15.4 Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.15.5 Pharmaron Beijing Recent Developments
- 12.16 Asymchem Laboratories (Tianjin)
- 12.16.1 Asymchem Laboratories (Tianjin) Company Information
- 12.16.2 Asymchem Laboratories (Tianjin) Business Overview
- 12.16.3 Asymchem Laboratories (Tianjin) Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.16.4 Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.16.5 Asymchem Laboratories (Tianjin) Recent Developments
- 12.17 Porton
- 12.17.1 Porton Company Information
- 12.17.2 Porton Business Overview
- 12.17.3 Porton Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.17.4 Porton Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.17.5 Porton Recent Developments
- 12.18 SEQENS
- 12.18.1 SEQENS Company Information
- 12.18.2 SEQENS Business Overview
- 12.18.3 SEQENS Revenue in Biologics Clinical Manufacturing CDMO Service Business (2021-2026)
- 12.18.4 SEQENS Biologics Clinical Manufacturing CDMO Service Product Portfolio
- 12.18.5 SEQENS Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst